Hep C Discussion Forum

Full story here:  http://www.fiercepharma.com/story/eu-nod-sets-gileads-harvoni-record-breaking-sales/2014-11-18

"But Europe, like the U.S., has already given some indication that it may have trouble affording the drug, which checks in at $94,500 per 12-week treatment course in the U.S. Though Gilead offered up predecessor Sovaldi at a deep discount of £35,000--and the U.K.'s notoriously strict watchdogs deemed it cost-effective--National Health Service documents seen by Pharmafilelater suggested the government couldn't bear the aggregate cost of treating 20,000 U.K. patients."